Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

NCT00364364 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Loss of funding

Conditions

Pancreatic Cancer

Interventions

DRUG: Radiolabeled humanized PAM4 IgG

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]